Showing 1721-1730 of 3223 results for "".
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- Oculis Begins Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-begins-phase-3-optimize-2-trial-of-ocs-01-for-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2482022/Oculis Holding announced 'First Patient First Visit' (FPFV) in the OCS-01 phase 3 OPTIMIZE-2 trial for the treatment of inflammation and pain following cataract surgery. Data from the phase 3 OPTIMIZE-2 trial is intended to support the company’s NDA submission to the FDA. If ap
- Oculis Commences Stage 2 of Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in DMEhttps://modernod.com/news/oculis-announces-first-patient-first-visit-in-phase-3-diamond-1-trial-of-ocs-01-eye-drop-in-dme/2482015/Oculis Holding announced that the 'First Patient First Visit (FPFV)' in stage 2 of its phase 3 DIAMOND-1 trial evaluating OCS-01 for the treatment of DME. DIAMOND-1 is a phase 3, two-stage, double-masked, randomized, multicenter trial to assess the efficacy and sa
- Visus Therapeutics Completes Enrollment in BRIO-I Phase 3 Trial of Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-completes-enrollment-in-brio-i-a-phase-3-clinical-trial-of-brimochol-pf-for-the-treatment-of-presbyopia/2481483/Visus Therapeutics announced it has completed patient enrollment and the last visit had been conducted in BRIO-I, a phase 3 trial for its lead asset, Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia. “We are thrilled to have reache
- AI Can Identify Heart Disease From an Eye Scanhttps://modernod.com/news/ai-can-identify-heart-disease-from-an-eye-scan/2480602/Scientists have developed an artificial intelligence system that can analyze eye scans taken during a routine visit to an optician or eye clinic and identify patients at a high risk of a heart attack, according to a University of Leeds, UK, news release. Doctors have recognized th
- Kubota Vision Initiates PBOS Prospective Study in Patientshttps://modernod.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/Kubota Vision announced that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using the company's Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device. The study is being led by S
- Updated Cataract PPP Raises Questions About Same-Day Bilateral Cataract Surgery and Office-based Cataract Surgeryhttps://modernod.com/news/updated-cataract-ppp-raises-questions-about-same-day-bilateral-cataract-surgery-and-office-based-cataract-surgery/2480467/The American Academy of Ophthalmology recognizes that immediate sequential bilateral cataract surgery (ISBCS) has the potential for some positive implications for patients. These include reduced out-of-pocket expense and fewer total visits to health care facilities. ISBCS has been adopted to a gr
- OneSight Partners With Anthem Blue Cross and Blue Shield Foundation to Provide Free Eye Exams and Glasses in Cincinnatihttps://modernod.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/Preventative care visits have dropped significantly over the course of the pandemic, and this is especially true in under-served communities. That’s why the Anthem Blue Cross and Blue Shield Foundation teamed up with OneSight, a leading global vision care nonprofit, to provide free eye exams and
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c
- Why Johnson & Johnson is Investing in This Niche Telehealth Startuphttps://modernod.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare